Christopher Singh, MD
Ophthalmology · Grand Blanc, MINPI 1083724900
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,021 of the $13,353 with a category attached, or 60.1%. Alimera Sciences, Inc. accounts for 80.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $5,133 and has fallen 71.1% since, to $1,483 in 2025. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 84 payments — averaging $158.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$11K
- ANI Pharmaceuticals, Inc.$1K
- Novartis$338
- Genentech USA, Inc.$233
- Regeneron Healthcare Solutions, Inc.$126
- Apellis Pharmaceuticals, Inc.$126
- plus $407 from 9 others
Across 9 payments — averaging $3176.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alimera Sciences, Inc.$16K
- Eyepoint US, Inc.$9K
- ANI Pharmaceuticals, Inc.$4K
What the payments were for
- Speaking & faculty fees$5,31340%
- Food & beverage$8,02160%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,353 in reported general payments places this provider in the 90th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 197 | $17,914 |
| Prednisolone Acetate | 177 | $11,771 |
| Ketorolac Tromethamine | 76 | $3,027 |
| Dorzolamide Hcl | 111 | $2,311 |
| Brimonidine Tartrate | 64 | $546 |
| Ofloxacin | 39 | $523 |
| Atropine Sulfate | 12 | $506 |
| Timolol Maleate | 16 | $254 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Grand Blanc
- Ankur MehtaGrand Blanc$11K
- Amy ZhangGrand Blanc$10K
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
- Jason MillerAnn Arbor$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.